May 11, 2020 / 10:51 PM / 15 days ago

BRIEF-AcelRx Pharmaceuticals Reports Q1 Loss Per Share $0.20

May 11 (Reuters) - AcelRx Pharmaceuticals Inc:

* ACELRX PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

* Q1 REVENUE ESTIMATE $1.9 MILLION — REFINITIV IBES DATA

* Q1 EARNINGS PER SHARE ESTIMATE $-0.17 — REFINITIV IBES DATA

* PROVIDES UPDATES ON TETRAPHASE TRANSACTION

* EXPECTS TO SEE STRONG VOLUME OF ORDERS FROM U.S. MILITARY FOLLOWING MILESTONE C APPROVAL FOR DSUVIA

* ACELRX PHARMACEUTICALS - YEAR-END 2020 REMS-CERTIFIED FACILITIES, FORMULARY APPROVALS GOALS WILL BE RE-EVALUATED ONCE COVID-19 RESTRICTIONS ARE LIFTED

* CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS BALANCE OF $52.7 MILLION AS OF MARCH 31

* ACELRX - REGARDLESS OF WHETHER TETRAPHASE CHOOSES TO ACCEPT OFFER OTHER THAN CO’S, CO-PROMOTION DEAL BETWEEN 2 COS WOULD REMAIN IN PLACE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below